In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX). Dr. Bokhari outlines Medicus Pharma’s distinctive strategy of acquiring de‑risked, mid‑stage therapeutic assets and advancing them through Phase 2 development to attract major pharmaceutical partners. The discussion centers on the company’s two lead programs- Skinjet, a novel microneedle patch offering a non‑invasive alternative to surgery for non‑melanoma skin cancer, and Teverelix, a next‑generation therapy targeting prostate cancer and urinary retention. Dr. Bokhari elaborates on the company's strategic integration of generative AI through a partnership with Reliant AI to optimize clinical trial efficiency and outlines Medicus Pharma’s financial strategy, focusing on upcoming data readouts and non-dilutive capital through out-licensing opportunities.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer. The conversation centers on NurExone’ lead product, ExoPTEN, a therapeutic platform that combines exosomes with siRNA to promote nerve regeneration in multi-billion dollar markets like spinal cord and optic nerve injury. Dr. Shaltiel outlines the company’s strong preclinical evidence, its de-risked characteristics bolstered by Orphan Drug Designation in both the US and Europe, and the company's multi-layered patent strategy. He also highlights NuRexone' unique US-based manufacturing model designed to generate revenue within the next year as they move toward clinical trials.

In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, with a particular focus on advancing the norovirus program due to high global unmet need. Martin outlines the ongoing human challenge norovirus study at Emory University, CDI‑988’s potential as therapy and prophylactic, and growing U.S. government and military interest. The episode also highlights the company' upcoming milestones, including mid‑2026 top-line data for the CDI-988 human challenge study, and an overview of its broader pipeline, including influenza A and B programs.

Best,